Centessa Pharmaceuticals PLC
Change company Symbol lookup
Select an option...
CNTA Centessa Pharmaceuticals PLC
ZVSA Zyversa Therapeutics Inc
MYMD MyMD Pharmaceuticals Inc
$NQUSS302050EUR Nasdaq US Small Cap Open End and Mis
JOBY Joby Aviation Inc
RVLP RVL Pharmaceuticals PLC
PDO PIMCO Dynamic Income Opportunities Fund
BOCT Innovator U.S. Equity Buffer ETF™ October
BAC Bank of America Corp
YARIY Yara International ASA

Health Care : Biotechnology |
Based in United Kingdom
Company profile

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Day's Change
0.2064 (3.74%)
B/A Size
Day's High
Day's Low

Today's volume of 11,283 shares is on pace to be in-line with CNTA's 10-day average volume of 84,140 shares.


Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.